Business
Issuance of New European Patent Bolsters IP Protection for Jaguar Health in the Treatment of Congenital Diarrheal Disorders (CDDs)
New patent issued for core rare disease target indication for crofelemerJaguar has approximately 200 patents issued and pendingJaguar is supporting
About this update from Jaguar Health, Inc.
[{"type":"text","content":"New patent issued for core rare disease target indication for crofelemerJaguar has approximately 200 patents issued and pendingJaguar is supporting investigator-initiated proof-of-concept studies of crofelemer for the rare disease indications of short bowel syndrome (SBS) and microvillus inclusion disease (MVID), an ultrarare CDD, in the US, EU, and Middle East/North Africa regions, with proof-of-concept results expected before the end of 2024 and throughout 2025 SAN FRANCISCO, CA / ACCESSWIRE / July 31, 2024 / Napo Pharmaceuticals (Napo), a Jaguar Health (NASDAQ:JAGX) (Jaguar) family company, today announced that the European Patent Office has issued a new patent to Napo for methods of preventing, ameliorating and/or treating diarrhea associated with congenital diarrheal disorders (CDDs) using a proanthocyanidin polymer composition such as crofelemer, Napo's novel plant-based prescription drug.\"We are very happy that this patent has been issued and believe that it further enhances our intellectual property protection for crofelemer for our core rare disease target indication of MVID, an ultrarare CDD,\" said Lisa Conte, Jaguar's founder, president, and CEO.\"As previously announced, Jaguar, with strong leadership and participation from Jaguar family companies Napo and Napo Therapeutics, is supporting third-party, investigator-initiated proof-of-concept studies of crofelemer for SBS with intestinal failure and MVID in the US, EU and Middle East/North Africa (MENA) regions, with results expected before the end of 2024 and throughout 2025,\" Conte said. \"In accordance with the guidelines of specific EU countries, published data from clinical investigations in SBS and MVID could support early patient access to crofelemer for these debilitating conditions in those countries.\"MVID is a severe infantile disease characterized by diarrhea, malabsorption, and acid/base instability, requiring intensive parenteral support for nutritional and fluid management, and there are currently no approved drug treatments.Some SBS patients are subject to intestinal failure, often requiring parenteral nutrition (PN) from a few days up to 7 days a week. Intestinal failure is associated with significant morbidity and mortality; and high medical expenses associated with PN. SBS patients with intestinal failure also have severe chronic diarrhea, and the...